The australia pet nutraceuticals market is anticipated to grow from USD 28.40 million in 2025 to USD 30.90 million in 2026 and is forecast to reach USD 56.40 million by 2031, with a CAGR of 12.79% during 2026-2031. This report is Segmented by Sub Product (Milk Bioactives, Omega-3 Fatty Acids, Probiotics, Proteins and Peptides, Vitamins and Minerals, and Other Nutraceuticals), by Pets (Cats, Dogs, and Other Pets), and by Distribution Channel (Convenience Stores, Online Channel, and More). The Market Forecasts are Provided in Terms of Value (USD) and Volume (Metric Tons).
Other drivers and restraints analyzed in the detailed report include:
Milk bioactives is the fastest-growing segment, projected to grow at a 15.3% CAGR from 2026 to 2031. Although the market for milk bioactives is smaller, it is becoming increasingly significant in premium feline nutrition, where specialized positioning is more important than market size. Oversight by the Australian Pesticides and Veterinary Medicines Authority (APVMA) is particularly critical for sub-products marketed with strong health-related claims. As consumer demand increases, companies in the Australian pet nutraceuticals market must exercise caution in their claims. While proteins and peptides are gaining attention, there is a growing focus on providing targeted muscle and tissue support for senior and active dogs.
Australia Pet Nutraceuticals Market Trends and Insights
Preventive Pet Healthcare Spending
Preventive supplementation has moved from an occasional purchase to a recurring spending line for many Australian households, and that shift is supporting the Australia pet nutraceuticals market. Animal Medicines Australia reported that dog-owning households spent AUD 2,520 (USD 1,634) per year on their pets in 2025, indicating the budget capacity for routine care rather than one-off treatment spending. This matters because supplements are being integrated into daily feeding habits rather than purchased only when a problem becomes visible. Once a product becomes part of an everyday routine, reorder cycles become steadier and brand retention improves. That change expands the addressable base for the Australia pet nutraceuticals market beyond households dealing with a current condition. It also supports better revenue visibility for brands that can secure repeat use with simple formats and clear wellness positioning.Pet Humanization and Premium Wellness
The financial significance of pets in Australian households continues to grow, driving demand for higher-value products in the Australian pet nutraceutical market. According to Animal Medicines Australia, national pet spending reached AUD 21.3 billion (USD 13.8 billion) in 2025, up 35% from the revised 2022 total of AUD 15.7 billion (USD 10.2 billion). This trend indicates that pet care is evolving beyond basic maintenance, with consumers prioritizing tailored and wellness-focused products. As a result, premium formats are perceived less as a cost barrier and more as a sign of responsible pet ownership. In the Australian pet nutraceuticals market, brands that align products with life stage, breed-specific needs, and clear purposes are better positioned to sustain pricing and encourage repeat purchases. This dynamic has attracted both specialized supplement brands and larger animal health companies to the category.Regulatory Ambiguity Around Therapeutic Claims
Regulatory uncertainty regarding therapeutic claims remains a significant challenge in the Australian pet nutraceuticals market. The Australian Pesticides and Veterinary Medicines Authority (APVMA) has clarified that using less definitive language, such as "may help," does not exempt therapeutic treatments from regulatory requirements, and authorization may still be necessary before including such claims in product materials. The APVMA then issued revised guidance effective May 1, 2025, clarifying that qualifying products under Excluded Nutritional or Digestive criteria would not need full registration as veterinary chemical products. Even with that clarification, imported brands still face stricter claim discipline in Australia than in some other markets, which can slow launches and require label review or reformulation. This keeps compliance cost and timing risk high in the Australia pet nutraceuticals market for companies that want to market stronger functional outcomes.Other drivers and restraints analyzed in the detailed report include:
- Veterinary Endorsement and Supplement Credibility
- Aging Pets and Mobility Needs
- Ingredient Sourcing Volatility for Specialized Actives
Segment Analysis
Probiotics are projected to account for the largest share of the Australia pet nutraceuticals market in 2025, representing 28.0%. This positions them as the leading sub-product across both veterinary-led and direct-to-consumer segments. Vitamins and minerals remained the second major demand pillar because they fit a broad range of life stages and price points. Omega-3 fatty acids also held a growing position because they align with skin and allergy management, a concern that stays visible in routine care. This gives the Australia pet nutraceuticals market a sub-product mix where everyday digestive support leads, while broad wellness and skin support continue to anchor adjacent demand.Milk bioactives is the fastest-growing segment, projected to grow at a 15.3% CAGR from 2026 to 2031. Although the market for milk bioactives is smaller, it is becoming increasingly significant in premium feline nutrition, where specialized positioning is more important than market size. Oversight by the Australian Pesticides and Veterinary Medicines Authority (APVMA) is particularly critical for sub-products marketed with strong health-related claims. As consumer demand increases, companies in the Australian pet nutraceuticals market must exercise caution in their claims. While proteins and peptides are gaining attention, there is a growing focus on providing targeted muscle and tissue support for senior and active dogs.
Complete Report Scope:
- By Sub Product
- Vitamins and Minerals
- Probiotics
- Omega-3 Fatty Acids
- Proteins and Peptides
- Milk Bioactives
- Other Nutraceuticals
- By Pet Type
- Dogs
- Cats
- Other Pets
- By Distribution Channel
- Convenience Stores
- Online Channel
- Specialty Stores
- Supermarkets/Hypermarkets
- Other Channels
List of Companies Covered in this Report:
- Mars, Incorporated
- Nestlé S.A.
- H&H Group Limited
- EBOS Group Limited
- Pet Circle Australia Pty Ltd
- Zoetis Inc.
- Virbac S.A.
- Nutramax Laboratories, Inc.
- Elanco Animal Health Incorporated
- FoodScience, LLC
- NOW Health Group, Inc.
- Vetafarm Pty Ltd
- Real Pet Food Company Pty Ltd
- The Hill’s Pet Nutrition, Inc.
- K9 Natural Limited
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Key Industry Trends
5 Supply and Production Dynamics
6 Market Size and Growth Forecasts (Value and Volume)
7 Competitive Landscape
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Mars, Incorporated
- Nestlé S.A.
- H&H Group Limited
- EBOS Group Limited
- Pet Circle Australia Pty Ltd
- Zoetis Inc.
- Virbac S.A.
- Nutramax Laboratories, Inc.
- Elanco Animal Health Incorporated
- FoodScience, LLC
- NOW Health Group, Inc.
- Vetafarm Pty Ltd
- Real Pet Food Company Pty Ltd
- The Hill’s Pet Nutrition, Inc.
- K9 Natural Limited
